|Bid||35.01 x 1800|
|Ask||35.52 x 1000|
|Day's Range||34.84 - 37.91|
|52 Week Range||20.60 - 99.27|
|Beta (5Y Monthly)||2.33|
|PE Ratio (TTM)||16.83|
|Earnings Date||Oct 24, 2022 - Oct 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.00|
Subscribe to Yahoo Finance Plus to view Fair Value for INMD
On Tuesday, InMode stock got a positive adjustment to its Relative Strength (RS) Rating, from 72 to 86. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced that senior management including Moshe Mizrahy, Chairman and Chief Executive Officer and Yair Malca, Chief Financial Officer, will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics one-on-one Conference on Tuesday, Aug. 16, 2022.
Shareholders of medical technology company InMode (NASDAQ: INMD) have not had a great 2022; the stock has fallen roughly 50% since the beginning of the year. Here are three reasons to consider InMode as a long-term growth stock for your portfolio. InMode designs and builds non-invasive medical equipment for cosmetic procedures like face and body contouring, hair removal, and women's wellness.